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1. Introduction
The need for artificial organs and implants
to repair and/or replace damaged organs
and to correct congenital disabilities of
patients is increasing.[1–3] If fabricated
human-like organs or tissues are to be
effective and to function optimally, they
have to follow the hierarchical structure,
which is a prerequisite to mimic the com-
plex functions of the organs and tissues
found in nature.[4] The hierarchical struc-
tures of tissue are the nature of living
organisms, and the sizes of such structures
range from nanometers to micrometers;
furthermore, the definitive geometries of
artificial organs and tissues give them
many advantages, such as strength and bio-
logical interactions among subhierarchy
levels.[5,6] Interactions between cells and
of cells with the matrix surrounding them
happen freely and on all sides in the hier-
archical construct system.[7] Because the structures and functions
of that construct system are essential, human-like artificial
organs and tissues fabricated and used for regenerative medicine
must mimic that hierarchical structure.
The final goal of tissue engineering is to create artificial tissue
with the ability to perform biological functions. Nonetheless,
materials are a critical part of successful tissue engineering
for regenerative medicine. The materials’ properties, such as
size, stiffness, biocompatibility, and biodegradability, have to
be considered during material selection for tissue engineering.
Scaffolds have been described as an essential component under-
lying the successful formation of functional artificial tissues.[8,9]
Therefore, with a proper scaffold material, an adequate microen-
vironment for cell proliferation, cell adhesion, and cell–cell inter-
actions can be achieved.[10] Moreover, a suitable combination of
scaffold materials and cells defines the functionality of the hier-
archical tissue complex. The embodiment of cells during the fab-
rication process for cell-laden scaffolds and the incorporation of
live cells into the fabricated scaffolds are integral parts of the
organization of functionalized artificial tissues. For tissue regen-
eration, a scaffold, as the framework in tissue engineering, has to
provide the features that can induce cellular and biophysical
responses through the chemical compositions, elasticity, geom-
etry, and ligand spacing of the biomaterials to modulate the
behavior of cells.[11] The signaling cues from a synthetic polymer
can be increased by protein incorporation into and addition of
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As part of regenerative medicine, artificial, hierarchical tissue engineering is a
favorable approach to satisfy the needs of patients for new tissues and organs to
replace those with defects caused by age, disease, or trauma or to correct
congenital disabilities. However, the application of tissue engineering faces
critical issues, such as the biocompatibility of the fabricated tissues and organs,
the scaffolding, the complex biomechanical processes within cells, and the
regulation of cell biology. Although fabrication strategies, including the traditional
bioprinting, photolithography, and organ-on-a-chip methods, as well as combi-
nations of fabrication processes, face many challenges, they are methods that can
be used in hierarchical tissue engineering. The strategic approach to synthetic,
hierarchical tissue engineering is to use a combination of several technologies
incorporating material science, cell biology, additive manufacturing (AM),
on-a-chip strategies, and biomechanics. Herein, in a review, the current materials
and biofabrication strategies of various artificial hierarchical tissues are discussed
based on the level of tissue complexity from nano to macrosize and the adaptive
interactions between cells and the scaffolding surrounding the incorporated cells.
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biomimetic factors from the extracellular matrix (ECM) to scaf-
folds fabricated using synthetic polymers.[12] The cellular physi-
ology, including survival, migration, growth, and differentiation,
is determined by the microenvironment provided by the cells’
scaffold.[13] The biological interactions between the cells and
the scaffold are combinations of receptor-mediated and
mechanical-mediated signals, so-called mechanotransduction,
that regulate the phenotype and the function of the cells.
During this process, the cells will respond by convertingmechan-
ical stimuli into the ECM’s biochemical signals to the cells’
nuclei.[14,15] Mechanosensitive molecules in cells recognize those
mechanical stimuli and initiate the mechanotransduction pro-
cess.[16,17] Furthermore, biochemical molecules are synthesized
in the cytoplasm after mechanosensitive molecules bind to recep-
tors. Therefore, mechanotransduction, including mechanosens-
ing and mechanosignaling, is the core of cell–ECM interactions
that must be mimicked during tissue engineering for regenera-
tive medicine.
For the engineering of tissues for the purposes of regenerative
medicine, fabrication is an essential part of constructing a natu-
ral hierarchical structure, and many methods, for instance,
microfluidics for organ-on-a-chip (OOC) and additive manu-
facturing (AM) strategies, including inkjet-based, extrusion-
based, laser-assisted-based, and stereolithography-based 3D bio-
printing, have been used. The microfluidics for OOC fabrication
provides the minimal function of a tissue or organ and allows
tissue and organ constructs to be explored under minimal con-
ditions. This microfluidic approach to fabrication allows micro-
environment tissue-based signaling to be simulated in a 3D
tissue culture in a similar way as in in vivo applications. In con-
trast, 3D bioprinting yields improved cell organization with
respect to classical tissue engineering with matrices throughout
the scaffold and ultimately produces artificial tissues and organs
with realistic, natural, hierarchical structures; moreover, 3D bio-
printing allows those natural structures to be mimicked layer-by-
layer, leading to the fabrication of different structures and differ-
ent compositions of materials and cells in the different layers of
the cell-laden scaffolds. However, the 3D bioprinting process
requires a biocompatible ink that contains biological materials
for the cells’ scaffold and living cells for tissue fabrication.[18]
If the complex, natural, hierarchical structures of tissues and
organs are to be mimicked, the ultimate strategies, including
material selection, the fabrication method, and the mimicking
of their microenvironment, must be fully understood. Thus, a
comprehensive discussion of this topic would include the
materials to be used, the fabricationmethod, and the engineering
of the fabricated scaffold to achieve the proper hierarchical
structure so that the fabricated tissue or organ can be used
for regenerative medicine.
2. Hierarchical Tissues
Living organisms are highly organized and structured, following
a hierarchy that can be examined on a scale from single mole-
cules to multicellular aggregates.[19] The definition of hierarchy
encompasses objects with different dimensions and scales with
anisotropic links between them. For instance, as the body’s larg-
est organ, skin comprises three layers, the epidermis, dermis,
and the hypodermis, that vary significantly in their anatomies
and functions.[20] The epidermis layer incorporates several layers,
the stratum corneum, stratum lucidum, stratum granulosum,
stratum spinosum, and the stratum basale or germinativum,
as well as several residing cells, such as melanocytes, keratino-
cytes, Merkel’s cells, and Langerhans’ cells.[21] Tightly connected
to the epidermal basement membrane, the dermis consists of
papillary and reticular regions that comprise an interconnected
network of collagen and elastin fibers produced by fibroblast
cells.[22] Deep in the dermis, the hypodermis, as the deepest layer
of skin, connects the skin to the bones and the muscles’ under-
lying fascia.[23] Mimicking the hierarchical and unique structure
of an organ is essential if an artificial organ with functions and
characteristics similar to those of a real cell is to be constructed
while considering the biological tissue requirements and the
technical strategies (Figure 1).
The order of the highly structured, complex system of cells,
the ECM, and cell signaling is the basis of the 3D microenviron-
ment in natural tissues.[24–26] From the 1D biological building
blocks to the 2D monolayer culture model of cells, the orienta-
tions of the cells in the ECM on the substrate’s surface and of the
cell-to-cell adhesions in the horizontal and the vertical planes lead
to a complex 3D structure. In 3D, cells can initiate adhesions on
all surfaces, but the surrounding matrix constrains cell migra-
tion.[7] In vivo, cultured 3D cells show more relevant behaviors
and conditions, including cell adhesion, migration, mechanics,
proliferation, differentiation, and responses to signaling mole-
cules, than they do in the 2D cell model.[27–31] Due to cells’
dimensionality, different native hierarchical levels need to be
imitated artificially by controlling the functional molecular sub-
units that differ in size from nanometer to micron scale. In addi-
tion, time is considered an influential factor in the reactions of
the properties of artificial tissues to alterations and interactions
with the environment of the native tissue.[32,33]
In the hierarchical system of natural tissues, cells interact with
similar and different cells to form communication between cells,
and they play essential roles in tissue morphogenesis and func-
tion.[34–36] Cells interact with neighboring cells through direct
and indirect mechanisms. Direct cell communication or cell–cell
interactions occur through cell junctions and long-distance
mechanical communication through the ECM.[37–39] Indirect
cell–cell communication is conducted by soluble factors in the
cell’s microenvironment, such as basic nutrients and cell signal-
ing molecules.[40] The ECM, which surrounds the cells in abun-
dance, provides various cell adhesion ligands that will bind with
the receptors on the cells’ surfaces for transducingmicroenviron-
mental signals from ormediated by the ECM.[41,42] The ECM pro-
vides cells with biophysical properties and cues, including the
structural mesh, the mechanical stiffness of the network, and
variations in the macromolecules. The cells’ behavior, perfor-
mance, and functions in tissues are affected by the structural fea-
tures of the ECM, such as its hierarchical order and the
arrangement of the ECM fibers and pores that are formed in
the occupying interstices of the ECM networks.[43–45] From tissue
to tissue, the anisotropic structures of ECM fibers, which are
hierarchically organized, can differ tremendously.[46]
Cell differentiation toward functional tissues, such as skin,
bone, neural tissues, cardiomyocytes, etc., is modulated by the
presence of cell signaling biomolecules (e.g., growth factors,
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transforming growth factor beta, chemokines, cytokines, and
genes) and by physical stimuli (e.g., physical forces, as well as
cell–ECM and cell–cell physical contact).[47] In tissue engineer-
ing, if the hierarchy of biological tissue is to be fabricated, the
signaling molecules, i.e., biomaterials with or without synthetic
materials, must be incorporated through biofabrication to form a
well-defined, biodegradable, porous, polymeric scaffold to induce
desired cell responses from the seeded cells, leading to engi-
neered tissues and organs.[48,49] Scaffolds play a vital role in this
approach as they provide support for cell adhesion, and the cells
proliferate, differentiate, and grow to form new tissues or organs.
Ideally, scaffolds should possess a specific pore size that allows
cells to spread, be biologically degradable and compatible, and
have mechanical features.[50] Another way is to incorporate on
a nano or microscale a single unit that can be utilized as a build-
ing block to construct tissue on a larger scale.[51,52] These modu-
lar units can be made using biofabrication methods, such as self-
assembled aggregation, cell sheeting, microfabrication of cell-
laden scaffolds, or 3D direct cell printing.[53–55]
The human body has the capability to regenerate its damaged
tissue, but the degree of regeneration is limited due to several
factors, including the type of tissue and its complexity, as well
as the wound’s size and severity.[56] An artificial tissue in regen-
erative medicine is a tissue made from a single biomaterial or
from a combination of biomaterials and synthetic materials that
systemically mimics the native tissue and is used for therapeutic
applications to substitute for or restore the native tissue’s func-
tion in the damaged area. The construction of artificial tissues
with biomimetic forms and designs that aim to recapture the
complex hierarchy and biofunctionality of human tissue is nec-
essary if regenerative medicine is to be advanced and drug
screening and disease models are to be developed.[57] An
OOC using human cells is a promising development in regen-
erative medicine for recapturing the human physiological
conditions and for integrating more than one tissue type to inves-
tigate a drug’s efficacy and safety.[58] Furthermore, artificial tis-
sues are tested in animal models as a preclinical test before being
implanted in humans.[59] Therefore, materials with regenerative
properties need to be made at different hierarchical levels.
Because an organ-like microarchitecture must replicate the
organ’s structure, geometry, and functionality, both multiscale
structural designs and functional building blocks are critical.
3. Fabrication Tools and Techniques
3.1. Effects of AM on Tissue Engineering
The fabrication technique plays an essential role in the success of
hierarchical tissue engineering for regenerative medicine pur-
poses. Several strategies, such as electrowriting, electrospinning,
and AM, have been developed and being utilized to model hier-
archical tissue engineering.[60–63] Electrowriting and electrospin-
ning use an applied voltage to induce the collection of a stable
fluid on a collector plate. The main difference between these
two methods is the electrical instabilities caused by the applied
voltage. In electrowriting, the function of the electrical instabil-
ities is to generate a continuous fluid with a low flow rate on the
collector plate. However, in the electrospinning method, electri-
cal instabilities are used to drag a fiber onto the collector plate.
Even though both methods involve the deposition of a fluid, nei-
ther is considered to be an AM process because of the dynamics
of fiber deposition.[64] This dynamic process causes a fiber depo-
sition instability in comparison with the AM process and differs
from the AM process.
The AM process, or 3D printing technology, is a standard
method for fabricating hierarchical tissues for regenerative med-
icine. The 3D printing method provides not only high precision
Figure 1. An illustration of hierarchical regenerative tissues. Skin is an example of a multilayered tissue with hierarchical architectures: i) Stratum corneum,
ii) stratum spinosum, iii) stratum germinativum, and iv) ECM fibers. Technical strategies capable of satisfying biological requirements must be developed
and utilized complementarily.
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but also high cell organization in the scaffold. Moreover, in
regenerative medicine technology, 3D printing is commonly
used for scaffold construction to facilitate cell growth to replace
and repair tissues or organs damaged by an accident or congeni-
tal disabilities. The 3D printing process not only provides the
scaffold for cell proliferation but also constructs a cell-laden scaf-
fold. Such a printing process that uses a biocompatible ink with a
biological material and living cells is called 3D bioprinting.[18]
The ink used in 3D bioprinting is a material consisting of living
cells and a biomaterial or material with properties similar to
those of the ECM components.[65] Layer-by-layer fabrication
using 3D bioprinting can mimic a tissue’s or organ’s hierarchical
structure, so an artificial tissue or organ can be designed by using
a computerized 3D designer application to duplicate the complex
structure of that tissue or organ hierarchically. Moreover, the
integration between desirable and specific material properties
has become a favorable approach for tissue engineering and
regenerative medicine technology. Four basic approaches,
which are discussed in the following sections , are commonly
used in bioprinting fabrication: inkjet-based, extrusion-based,
laser-assisted-based, and stereolithography-based bioprinting,
which are shown in Figure 2 and Table 1.
3.1.1. Inkjet Bioprinting
Inkjet bioprinting is a necessary bioprinting technology with the
same basic principle as the conventional inkjet printing method,
but with a biomaterial as the bioink, which is used in place of the
conventional ink.[18,66] The printing device itself must also be
modified to include a heater or piezoelectric actuator, which will
allow the device to create a pulse that causes liquid from the
cartridge to drop onto the substrate, thereby starting the fabrica-
tion of a specific scaffold based on the desired design.[18,67] Inkjet
bioprinting, which is commonly used in tissue engineering and
fabrication, is a fast printing process that is cost-effective, has
high cell viability, and can produce several designs in a short
time. However, this process has several problems: the size of
the droplet is not uniform, the bioink can clog the nozzle,
and temperature and pressure can place mechanical stress on
the cells; these are summarized in Table 1.[18]
Artificial cartilage can be fabricated using inkjet-based bioprint-
ing with a composite bioink made from polyethylene glycol dime-
thacrylate (PEGDMA) combined with gelatin methacryloyl
(GelMA).[68] This composite bioink provides a suitable microenvi-
ronment for human mesenchymal stem cells (hMSCs) and allows
the development of cell differentiation during the initial stage.
Harnessing the crosslinking step tomimic the specific mechanical
strength of natural bone and cartilage tissue can improve the
mechanical properties of the 3D-bioprinted cartilage tissue’s scaf-
fold, increase the scaffold’s strength through layer-by-layer photo-
crosslinking, and enhance the differentiation of osteogenesis and
chondrogenesis in the hMSCs. The cells are well distributed
throughout the scaffold when using inkjet bioprinting.[68,69]
Artificial blood vessels were successfully created using the ink-
jet bioprinting method. The speed of the printing process was
found to play an essential role because a specific printing speed
is required to create a fine line.[69] Collagen has also been used in
bioinks for artificial skin fabrication using inkjet bioprinting.
Autologous fibroblasts are used in the bioink because they per-
form better during therapy and cause neither infections nor com-
plications. Such cells can reduce contraction and induce dermis
epithelialization, leading to wound healing.[1] The in situ inkjet
bioprinting process, which holds potential for fabricating the
Figure 2. Different 3D bioprinting techniques: A) Inkjet-based, B) extrusion-based, C) laser-assisted, D) stereolithography-based, and E) in situ inkjet
bioprinting processes. Reproduced under the terms and conditions of the Creative Commons Attribution license 4.0.[1] Copyright 2019, The Authors,
published by Springer Nature. F) Morphological and histological features of artificial skin fabricated using extrusion-based 3D bioprinting. Reproduced
with permission.[73] Copyright 2017, Wiley-VCH. G) Artificial bone disk fabricated using the in situ LAB process. Reproduced under the terms and
conditions of the Creative Commons Attribution license 4.0.[84] Copyright 2017, The Authors, published by Springer Nature. H) Artificial vascular graft
fabricated using stereolithography-based 3D bioprinting. Reproduced with permission.[87] Copyright 2016, Wiley-VCH.
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hierarchical structure of tissue due to its simplicity, easy control
of the droplet size, and capability to produce specific designs, is
shown in Figure 2A.
3.1.2. Extrusion-Based Bioprinting
Extrusion-based bioprinting, a fabrication strategy to construct a
3D structure layer-by-layer both in the vertical and the horizontal
directions, is the most popular bioprinting technique used in tis-
sue engineering in regenerative medicine.[66] Moreover,
extrusion-based 3D bioprinting is well known to be a promising
approach for fabricating hierarchical tissue. Due to its ability to
use different bioink materials to fabricate tissue structures layer-
by-layer, tissue constructs with different shapes and tissue scaf-
folds can be fabricated. However, a printable bioink with favor-
able properties, such as suitable viscosity and mechanical
properties, must be used to fabricate 3D-bioprinted tissue with
good physiomechanical and biological properties so that cells can
adapt and survive. Low stiffness is also a must for cell growth,
and the degree of crosslinking must be sufficient both to support
cell proliferation during the fabrication of new tissue and to
transport oxygen and nutrients to the cells.[70] However, when
using extrusion-based bioprinting, several issues, such as low cell
viability when high pressure is used, can occur; moreover, the
interplay between speed and pressure is not easy to control.
These characteristics are summarized in Table 1. That extrusion-
based 3D bioprinting has been used to bioengineer several
parts of the human body, e.g., bone,[71,72] skin,[73,74] cartilage,[75–77]
and adipose[78] and neural tissues,[79,80] is noteworthy.
Artificial bone and bone scaffolds have been bioengineered
through extrusion-based 3D bioprinting with several
biomaterials, and synthetic polymers, such as polylactic
acid–hydroxyapatite (PLA–HA)[72] and polycaprolactone
(PCL),[71] are common polymers used as bioinks. Artificial bone
was fabricated through indirect 3D bioprinting via a molding
process,[72] with the mold being fabricated using extrusion-
based 3D printing and the artificial bone being fabricated using
the molding process. Perfusion is an additional step introduced
to produce a highly, evenly porous scaffold to generate higher
cell distribution, cell proliferation, and cell viability. PCL with
dimethyl sulfoxide (DMSO) as a solvent has also been used as a
bioink because DMSO can increase the porosity of PCL so as to
increase cell adhesion, migration, and proliferation. Different
compositions of PCL and DMSO have been used to produce
3D-bioprinted cell-laden scaffolds exhibiting different cell via-
bilities, mechanical properties, and cell adhesions.[71]
Table 1. Bioprinting characteristics in hierarchical tissue-engineering applications.
No Bioprinting approaches Bioprinter characteristics Application Ref.




Cells well distributed in the scaffold
Issues in this bioprinting:
Nozzle clogging
Non-uniform droplet size
Mechanical stresses on cells due to temperature
and pressure
In situ inkjet bioprinting process of
autologous skin cells on a wound’s
surface.[1]
[1,18,68,239,240]
2 Extrusion bioprinting Resolution: 150–600 μm
Different layers with different structures
Use of different materials due to the use of
several different printing heads
High reproducibility
Issues in this bioprinting:
Low cell viability if high pressure is used
Printing process not easy to control, combination
between speed and pressure
Artificial skin fabricated using
extrusion-based 3D bioprinting.[73]
[18,73,241]
3 Laser-assisted bioprinting Resolution: 5–100 μm
Nozzle-free printing avoids nozzle clogging.
Noncontact process generates high cell viability.
Fast with very high resolution
Issues in this bioprinting:
Possibility of toxicity due to the photoinitiator
Limitations of printable materials
Artificial bone disk model.[84] [81,84,242]
4 Stereolithography bioprinting Resolution: 50–200 μm
Nozzle-free bioprinting prevents clogging.
High resolution
High cell viability
Issues in this bioprinting:
Cell damage caused by UV exposure during printing process
Artificial vascular graft fabrication. [66,87,243,244]
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Alginate, gelatin,[73] and silk fibroin (SF)[74] have been used as
bioinks for skin engineering via 3D bioprinting with an
extrusion-based approach because this method, as compared
with an in vivo system, can generate the hierarchical structure
and the composition of artificial skin by creating a dermis system
with a composition and organization similar to those of a mature
tissue’s cellular structure, as shown in Figure 2F[73] and Table 1.
This 3D-bioprinted artificial skin was first bioengineered as
scaffold-free skin to have the full thickness with human skin
cells. With this technique, artificial skin can be fabricated
quickly, and the cells can be evenly spread over the 3D-bioprinted
artificial skin.[73] In addition to the aforementioned, gelatin–
sulfonate–SF bioink was used to 3D bioprint artificial skin with
the foreskin fibroblasts from a child incorporated.[74]
Norbornene-modified hyaluronic acid (NorHA),[77] GelMA
and polyethylene glycol-methacrylate (PEG–MA),[75] and alginate
and poly (ethylene glycol) diacrylate (PEGDA)[76] are generally
used as bioinks during extrusion-based 3D bioprinting because
they have adequate properties for fabricating artificial cartilage.
Furthermore, in regenerative medicine, extrusion-based robot-
assisted 3D bioprinting with bioactive materials was used for car-
tilage bone restoration via an in situ printing mechanism.[76] In
addition, NorHA composite ink is a material that can potentially
be used for the fabrication of artificial cartilage because HA is
the natural material in cartilage. Moreover, in situ photo-
crosslinking with visible light is beneficial for the fabrication
of a dense cartilage structure, and a uniform strength is achieved
because the crosslinking takes place in every layer. This fabrica-
tion method can produce high cytocompatibility with a high and
even distribution of cell viability in the 3D-bioprinted cartilage
scaffold.[77] The GelMA and the PEGMA in 3D-bioprinted carti-
lage support the creation of hyaline-like cartilage, which allows
the formation of fibrocartilage.[75] A combination of collagen and
vascular endothelial growth factor (VEGF) was used to fabricate
synthetic neural tissue via an extrusion-based 3D bioprinting
technique.[79] The 3D-bioprinted VEGF with fibrin gel supported
the growth factor in the scaffold from collagen. Furthermore,
neural stem cells (NSCs) were incorporated into a polyurethane
composite bioink for neural tissue engineering.[80] The biode-
gradability of polyurethane makes it a potentially good choice
for neural tissue engineering. Because polyurethane can be syn-
thesized in different ways, how it is synthesized can affect the
proliferation of NSCs. In vivo application to animal wounds
showed that when the 3D-bioprinted NSC-laden polyurethane
scaffold was used, the recovery was better than it was without
that scaffold.
3.1.3. Laser-Assisted Bioprinting
Laser-assisted bioprinting (LAB) is generally known to be a
nozzle-free bioprinting method that uses a high-intensity laser
for cell patterning[66] with high speed and resolution while avoid-
ing nozzle clogging.[81] In this method, which has four main
components, the laser, the target, a biological component, and
the substrate on which the bioprinted materials are to be col-
lected, the laser is used as the source of energy required to print
the biomaterials on the substrate.[82] The components used in 3D
LAB bioprinting are two glass slides, one with a layer of a laser
absorbing substance and the other with a layer composed of the
biomaterial. The laser light passes through the laser absorbing
material and causes it to evaporate locally so that the pressure
drives a small amount of biomaterial onto the glass slide. A spe-
cific biomaterial pattern is generated by repeatedly moving the
glass slides, one and then the other, to create a 3D structure.[83]
The characteristics of LAB and the issues encountered during the
fabrication process are summarized in Table 1. The two most
common issues faced during LAB bioprinting are the possibility
of toxicity due to the photoinitiator and the limitations of print-
able materials.
Different cell types can be constructed in one 3D pattern when
using this LAB method because cells can be deposited with
microstructure resolution through computer control. This
method was successfully used for tissue engineering in artificial
skin fabrication,[83] and multilayer skin for patients with skin
damage was fabricated by combining collagen, NIH3T3 fibro-
blasts, and HaCat keratinocytes. This bioprinted skin was applied
in vivo to form new skin tissues. Not only skin but also bone has
been fabricated using the LAB method. In artificial bone fabri-
cation, a bioink, which is laden with mesenchymal stromal cells
(MSCs), collagen, and nano-HA as biomaterials, is used, as
shown in Figure 2G.[84] MSCs are used because these cells
are multipotent progenitors that can differentiate between
various cell types.
3.1.4. Stereolithography-Based Bioprinting
Another well-known type of nozzle-free bioprinting is
stereolithography-based bioprinting, which utilizes a digital
micromirror to control the light intensity at a specific printing
area to polymerize a light-sensitive polymer material.[66]
Stereolithography-based bioprinting uses an epoxy resin, a ther-
moplastic elastomer, a biomaterial-based hydrogel, and some
synthetic polymers modified to increase biocompatibility and
biodegradability.[85] Because this bioprinting method uses UV
irradiation, damage to the cell is possible. The details of
stereolithography-based bioprinting are summarized in Table 1.
Stereolithography is a bottom-up 3D fabrication method com-
monly used in dentistry, where stereolithography-based 3D bio-
printing is generally used to form an artificial denture base.
However, nowadays, even artificial teeth are being fabricated
by using this method to photopolymerize a methacrylate-based
biomaterial resin.[86] The bottom-up layer-by-layer deposition
of the material is adequate for constructing the hierarchical struc-
ture of a tooth, and such artificial teeth show good fracture resis-
tance because the layer-by-layer photopolymerization that occurs
throughout the 3D bioprinting increases the binding strength of
the methacrylate. The quality of 3D-bioprinted artificial teeth is
comparable to that of teeth fabricated using traditional methods.
Artificial bone was fabricated using stereolithography-based
bioprinting with a polypropylene fumarate resin.[85] However,
this bioprinting method requires a postcuring step that may
cause the printed product to shrink. In this method, the size
and the shape affect the 3D-bioprinted scaffold because the hier-
archical shape and structure are vital aspects in determining the
mechanical characteristics of artificial bone. Polypropylene fuma-
rate can also be used as an ink in vascular graft fabrication via
www.advancedsciencenews.com www.advnanobiomedres.com
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stereography-based 3D bioprinting, as shown in Figure 2H.[87] A
3D-bioprinted vascular graft was tested in vivo for several
months, as shown in Table 1, and 6 months after implantation
in mice, the artificial vascular graft showed suturability and
adequacy.
3.2. Microfluidics for Tissue Engineering
Because bioprinting provides an excellent avenue for tissue con-
structs, researchers around the globe are expending much effort
to investigate other methods to provide advanced approaches to
tissue modeling for regenerative medicine. Microfluidics was
developed to manipulate fluids on a microliter scale by using cap-
illary action, pumping, and electrowetting. Microfluidics has
been used for lab-on-a-chip (LOC) applications to deliver reagents
and analytes for various assay detection protocols.[88] After the
first attempts to use microfluidics to fabricate a cell culture plat-
form, it began to be used to fabricate platforms for tissue engi-
neering.[89] For tissue modeling toward regenerative medicine,
microfluidics uses OOC, which can be used for 3D tissue cul-
tures that can capture certain aspects of entire organs and organ
systems.[90–92] However, microfluidic technology is not currently
capable of building whole or hierarchical tissue; nevertheless, it
is a promising tool for modeling native tissues or organs with
minimal function and provides researchers with the freedom
to develop drug and tissue constructs, a very important step for-
ward in regenerative medicine in vitro.[92] Crucial features of
microfluidics that are the keys to tissue construction toward
regenerative medicine are the ability to be used for culturing cells
in a 3D structure and to simulate microenvironments for cell
development.[93] Although microfluidic technologies have
advanced the study of tissue engineering, microfabrication
through the use of microfluidics is a priority step that still needs
to be addressed.
3.2.1. Microfluidics in Hierarchical Tissue Fabrication
Microfabrication using microfluidics was initiated by the elec-
tronics industry to find a way to fabricate microelectronic chips.
The most common method and material used in 3D microflui-
dics to fabricate 3D cell cultures are photolithography and poly-
dimethylsiloxane (PDMS), respectively. Photolithography is a
very reliable method for precisely creating a microstructure; how-
ever, it involves many processes, such as making a master, clean-
ing, depositing a thin film photoresist, and etching, which must
be performed in clean room facilities. The use of PDMS in
microfluidics has various advantages, such as transparency,
which allows the biomaterial inside a microfluidic channel to
be optically observed, and gas permeability, which allows the oxy-
gen tension inside a microfluidic channel to be precisely
controlled.[94]
The functionality of the device that a study requires for specific
3D tissue modeling has to be taken into account when designing
the microfluidics. Also, the microenvironment must be con-
trolled, biophysical stimuli must be included, and the physiology
of the tissue cell must be captured.[58,92] For example, for micro-
fluidics to be used to fabricate a single-organ culture, such as a
heart, liver, kidney, lung, gut, skin, or brain culture, the
microfluidic system requires some important components for
inducing biophysical stimuli, such as hydrodynamic, electrical,
and mechanical stimuli, and for controlling the microenviron-
ment of the tissue being studied. The design of a microfluidics
system for fabricating a multiple-organ culture (blood–brain,
heart–heart, gut–liver, and liver–kidney–lung–neural) varies
because the designed system must allow connections and cross
talk between the organs, as well as the integration of biophysical
stimuli. As a result, the design of a microfluidic system for
multiple-organ interaction studies can be categorized into three
types: static, unidirectional single-pass, and recirculation.[92]
The design of a microfluidic system for fabricating a static tis-
sue culture is simple because a microfluidic channel for the flow
of a common medium is not needed, but a chamber for storing
cultured tissue is. This multiorgan cell culture platform consists
of shallow microwells that are used to culture cells for multiple
organs, such as the liver–kidney–lung, and for blood vessels.[95–97]
In contrast, another culture system, the unidirectional single-
pass tissue culture system, is designed for the purpose of connect-
ing one organ chamber to another via microfluidic channels.
These microfluid channels enable cross talk between the organs
through perfused microvessels. However, cross talk is only possi-
ble for organs located downstream, not organs located
upstream.[98] The microfluidic recirculation tissue culture system
is designed to have continuous circulation of a common medium
through multiple organs, mimicking the flow of blood through
blood vessels (Figure 3A).[99–102] Compared to the static and uni-
directional single-pass tissue culture system, this system has a
well-established external pumping system and microfluidic chan-
nels to control the hydrodynamics and the drug transport. In addi-
tion, the fluids effluent from the upper and the lower parts of
an organ can be directly transported to another organ and
collected for further analysis (Figure 3B–D).[99]
Although PDMS is a common material that has been used for
the fabrication of microfluidic channels because of its optical
transparency, durability, autoclave sterility, and biocompatibility,
the pristine surface of PDMS has to be modified to make the
surface suitable for culturing the cells because the surface of
PDMS is hydrophobic whereas it should be hydrophilic for better
cell attachment. The hydrophilic surface modification of PDMS
can be done by using a physisorption, oxygen plasma/physisorp-
tion, layer-by-layer, or immobilization method to coat the PDMS
with a functional material.[103] Another issue with the use of
PDMS is its high permeability, which allows hormones and
small molecules, such as drugs, to be absorbed. This issue
can be addressed by coating PDMS with a low-permeability mate-
rial, such as a lipid-based or poly(glycidyl methacrylate) (PGMA)
material or a material containing silica nanoparticles.[104–106] In
addition to PDMS, other materials, such as a tetrafluoroethylene-
propylene (FEPM) and styrene–ethylenebutylene–styrene (SEBS)
elastomer, have been used for microfluidic fabrication to resolve
the drug absorption issue.[107,108]
3.2.2. Microenvironment Stimulation in Microfluidics
Conventionally, cells are cultured in cell-culture dishes.
However, the microenvironment cues in that platform cannot
be controlled properly to establish a specific microenvironment
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in which cells can grow and develop into mature cells. Moreover,
this culture method fails to capture organ-level functions in vitro,
which is crucial for facilitating drug development for regenera-
tive medicine. In contrast, microfluidics can provide the features
needed to mimic native tissue constructs and to control the
microenvironment so that the physiological (hydrodynamic,
mechanical, and electrical) and the chemical microenvironments
needed to foster the function of native tissues can be simu-
lated.[58,93,109–111]
Hydrodynamic stimuli, such as a fluid shear force and a fluid
shear stress, can be generated in microfluidic systems by using
external pumping at a specific flow rate.[112–114] The microfluidic
channels act as vascular networks to produce solubility gradients,
as well as autocrine and paracrine signals. The fluid shear force is
very important for the correct biological functioning of endothe-
lial cells because it activates surface receptors and associated sig-
naling cascades.[115,116] Fluid shear stress, in contrast, is a
periodic mechanical stress that can be enabled in microfluidic
systems[117] and is a key differentiation parameter during the
physiological process. The fluid shear stress was applied to
mimic the environment of stem cells and to regulate their func-
tion and fate.[118,119] Jang et al. used fluid shear stress to control
the microenvironment to investigate its influence on both the
fluid reabsorption of aquaporin-2 and the orientation of actin
cytoskeleton.[120] They induced this stimulus by using a syringe
pump to cause the medium to flow through a PDMS-based
microfluidic system that had been integrated with a microporous
polyester membrane.
An electrical stimulus can be induced in a microfluidic system
by using cooperating conductive electrode arrays in this plat-
form.[121–126] Sun and Nunes engineered a system to stimulate
an electrical microenvironment by integrating two platinum
wires connected to two carbon rods.[127] Such a system allows
tissue to mature in vitro. Another electrical microenvironment
was constructed in a microfluidic system for continuously
regulating the differentiation of neuroepithelial stem cells
from patients.[128] The monitoring of the electrical microenviron-
ment was achieved by using a programmable system to differen-
tiate human neuroepithelial stem cells (hNESCs) into 3D
networks of dopaminergic neurons on a microfluidic titer plate.
Osaki et al. built a microfluidic system for the construction of
3D muscle bundles so that drug candidates can be tested and
found the pathogenesis of amyotrophic lateral sclerosis (ALS)
(Figure 4A–D).[129] They used electrical signals at different fre-
quencies to stimulate muscle contractions to study the perfor-
mance and the characteristics of motor neuron spheroids in a
microfluidic system (Figure 4E).[129]
Chemical microenvironments are crucial for the development
and function of cells and tissues. Microfluidics can be used for
the precise delivery of a liquid volume so that chemical gradients
Figure 3. A,B) Schematics of a microfluidics system that allows continuous circulation of common media through the system and collection of the fluid
effluent from organs, where aBlood refers to artificial blood and aCSF refers to artificial cerebral spinal fluid. C) The 3D pericytes, astrocytes, and endo-
thelial cells are cultured in a microfluidics system. D) Confocal fluorescence micrograph of neurons (β-III-tubulin) and astrocytes (glial fibrillary astrocytic
protein, GFAP) that are cultured together. The neurons and the astrocytes are green and blue, respectively. Reproduced with permission.[99] Copyright
2018, Springer Nature.
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can be maintained under the specific conditions required for tis-
sue development.[130–133] For example, muscle contractions were
produced by adding glutamic acid to a muscle cell culture that
had been fabricated using microfluidics (Figure 4F).[129] In addi-
tion, the chemical concentrations in microfluidic systems can be
controlled by reducing the permeability of the microfluidic
material.[103,104,134,135] For instance, Gökaltun et al. reduced
the permeability of PDMS by combining it with polyethylene gly-
col (PEG).[134] Also, their modified PDMS channel had a biocom-
patible, hydrophilic surface with long-term stability. The
adhesive surfaces for the stem cell niche were prepared by pat-
terning arrays of adhesive microwells. The adhesive surfaces
were produced by using a programmable CO2 laser to remove
the coated polyvinyl alcohol.[136] Chuah et al. improved cell adhe-
sion by coating polydopamine with collagen in a PDMS-based
microfluidic channel to give long-term stability to a bone marrow
stromal-cell culture.[137]
4. Materials for Hierarchical Tissue Fabrication
Materials have critical roles in the success of hierarchical tissue
engineering. The variations of materials characteristics, such as
size, biocompatibility, stiffness, and biodegradability, must be con-
sidered in material casting for tissue engineering purposes. A
combination of and a correlation between scaffold materials
and cells define the positioning of a complex, hierarchical tissue
system. A scaffold made of suitable materials exhibits an adequate
microenvironment for the proliferation of cells and generates cell
adhesion and cell–cell interactions.[10] The various materials that
are essential in hierarchical tissue engineering, such as synthetic
materials, biomaterials, and cells, will now be discussed.
4.1. Biomaterials
The biocompatibility and biodegradability of biomaterials for a
scaffold are critical aspects in tissue engineering. The chemical
composition, the structure, and the properties of a biomaterial
underlie the cell integration inside the scaffold and facilitate
the scaffold’s fabrication. Several kinds of biomaterials, for
instance, natural polymers and decellularized extracellular matri-
ces (dECMs), are used for tissue-engineering applications.
Gelatin,[138–141] alginate,[138,141,142] chitosan,[143,144] SF,[145,146]
and collagen[138,147] are common natural polymers with high
biocompatibility and biodegradability that can be used for
cell–scaffold purposes. The similar properties of gelatin and nat-
ural ECM provide the right conditions for cell migration and
make gelatin an excellent natural polymer for the cell’s scaf-
fold.[138,141] The subtle behavior of gelatin in mimicking the
ECM initiates cell proliferation, increases cell attachability,
and generates high cell viability in the scaffold.[141] Moreover, gel-
atin is abundantly available in nature.[148] Based on the purpose,
gelatin can be integrated with SF in the engineering of skin tis-
sue with properties that resemble those of natural skin, as shown
in Figure 5E.[74] Integration between the properties of gelatin and
the specific fabrication processes will create a hierarchical net-
work inside the gelatin scaffold and allow the fabrication of a
porous structure to support cell proliferation.[149]
The gelatin process with alginate can be easily customized and
modified so that other materials can be used. The lack of signifi-
cant toxicity makes alginate a biomaterial with high biocompatibil-
ity for use in scaffold fabrication.[142] In mammals, due to enzyme
deficiencies, alginate does not easily degrade, which can be over-
come by using crosslinking modifications.[138] The use of a hybrid
material, alginate modified using a dECM and methacrylate
Figure 4. A) A microfluidic system for a 3Dmuscle cell culture in which the
microfluidics surface is structured by using micropillars as a microenviron-
ment to which cells can attach. The muscle bundle was grown in a micro-
fluidics system, and the muscle fiber is attached the pillars on B) the 7th day
and C) the 21st day. Scale bars¼ 200 μm. D) Confocal fluorescence micro-
graph of a muscle bundle showing the pattern of the cells and their sarco-
meric structures. Scale bar¼ 50 μm. E,F) The variations with time of muscle
contractions powered by various microenvironment stimuli such as electri-
cal (at different frequencies) and chemical (glutamic acid at the 14th day)
stimuli, respectively. Reproduced from.[129] Copyright 2018, The Authors,
some rights reserved; exclusive licensee AAAS. Distributed under a
Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).
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reaction, leads to maximal mechanical properties, provides for cell
proliferation, and makes fabrication easy (Figure 5C).
In the fabrication strategy for artificial bone tissue, natural
materials, for instance HA and chitosan, are widely used to con-
struct the hierarchical structure. HA exhibits a proper pore size
for the growth of bone cells and has sufficient mechanical
strength for bone engineering.[150] A suitable pore size can be
achieved using sintering.[151] Figure 5B shows a HA scaffold
achieved by sintering for bone tissue engineering applications.
β-TCP-modified HA exhibits good biocompatibility with several
cells in the cell culture and has sufficient porosity for tissue engi-
neering, as shown in Figure 5D. In contrast, chitosan is a natural
biomaterial that is easily extracted from the shells of shrimps and
crustaceans. Its excellent characteristics, such as good mechani-
cal strength, biocompatibility, and biodegradability, as well as
nontoxicity, make chitosan a perfect candidate for medical and
tissue-engineering applications.[143,152] In the fabrication of arti-
ficial skin, a natural polymer with excellent biocompatibility,
environmental stability, and nontoxic response must be used.
Thus, natural polymers with those characteristics, such as SF,
are suitable for skin tissue engineering.[74] A scaffold made from
a gelatin–SF hybrid material exhibits better wound healing due to
the properties of SF, and the cells can be distributed evenly along
the scaffold. Furthermore, SF is biodegradable and provides an
adequate microenvironment for chondrocyte growth in cartilage
tissue engineering applications.[145] The high rejection rate dur-
ing the implantation process is the major drawback in SF-based
tissue engineering.[146] Because collagen is often found in skin,
connective tissue, cartilage, and bone as the ECM’s main protein
and provides an adequate microenvironment for cell prolifera-
tion,[138] it is widely used in tissue-engineering applications.[153]
4.2. Synthetic Materials
Because of the properties of natural polymers, with some mod-
ifications during synthesis, synthetic materials are excellent can-
didates for hierarchical tissue engineering. One of the common
synthetic polymers with good biocompatibility and biodegrad-
ability is PLA. It is suitable in scaffold hierarchical tissue engi-
neering of bone, neural, cardiovascular, and cutaneous
tissues.[154–158] PLA is commonly used in artificial bone tissue
engineering to fabricate a scaffold with a modified geometrical
structure. The scaffold’s pore size, which was between 0.2 and
0.35mm, was sufficient for cell proliferation while still providing
good mechanical properties for bone tissue engineering.[155]
However, PLA-based materials have fewer sites for cell attach-
ment and are, therefore, inadequate for cell adhesion.[154]
Surface modification of PLA by using a plasma treatment can
increase the attachment of cells to PLA.[158] Poly(lactic-co-glycolic
acid) (PLGA) has adequate properties for dental treatment pur-
poses and is used not only in dentistry but also for tissue grafts,
sutures, bone scaffolds, and drug delivery systems.[159,160] Wang
and colleagues enhanced the bioactivity of PLGA by coating it
with a nano-HA material. They found the cell viability and pro-
liferation to be higher than they were for PLGA without a nano-
HA coating.[161] PEG can modify PEGDA, which is commonly
used for body implants due to its biocompatibility and nontox-
icity, for drug delivery, and for regenerative medicine purposes,
by adding acrylate groups.[162,163] PEGDA has a low in vivo bio-
degradability, so a copolymer of PEGDA with poly(glycerol seba-
cate) acrylate (PGA) increases the degradation rate significantly
compared with PEGDA without any modification.[164] PCL has
an essential structure for bone tissue engineering and has good
Figure 5. Biomaterials and synthetic materials for tissue engineering. A) The 3D scaffold from a PCL-based material for bone tissue engineering.
Reproduced with permission.[71] Copyright 2020, RCS Publishing. B) The 3D-bioprinted micropores of HA for bone tissue engineering. Reproduced
with permission.[151] Copyright 2007, Elsevier. C) The 3D-bioprinted alginate and alginate/2Ma-dECM-based bioink. Reproduced with permission.[237]
Copyright 2020, Elsevier. D) Different cells cultured on different 3D-bioprinted β-TCP/HA scaffolds: cultures of human bone-marrow-derived mesenchy-
mal stem cells (HBMSCs) (squares), HUVECs (parallelograms), human umbilical vein smooth muscle cells (HUVSMCs) (triangles), and human dermal
fibroblasts (HDFs) (rectangles) after 1 and 7 days. Reproduced from.[238] Copyright 2020, The Authors, some rights reserved. Published by Elsevier LTD
on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. Distributed under a Creative Commons Attribution
NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND). E) The 3D-bioprinted gelatin scaffold (3DG), SF-coated 3D-bioprinted gelatin scaffold
(3DG–SF), and SF-derivative-coated 3D-bioprinted gelatin scaffold (3DG–SF–SO3). Reproduced under the terms and conditions of the Creative
Commons Attribution license 4.0.[74] Copyright 2017, The Authors, published by Springer Nature.
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biocompatibility and nontoxicity for medical implant pur-
poses.[138,165] The good mechanical properties (high strength)
and the large biodegradation rate of PCL allow its use for bone
fabrication in tissue engineering (Figure 5A). If the PCL surface
is modified using a plasma treatment and other polymers, such
as collagen and poly(methacrylic acid) (PMAA), the attachment of
cells on the PCL surface and the cell proliferation rate will be
enhanced.[166,167]
4.3. Cells in Tissue-Engineering Applications
Cells are essential in hierarchical tissue-engineering applications,
and cell–cell and cell–scaffold interactions are critical for tissue-
engineering success. Suitable cells and microenvironment sup-
port for cell proliferation are a must. Various cell types have been
used to fabricate skin, neurons, cardiac tissue, liver tissue, blood
vessels, andmusculoskeletal tissues.[168–171] The response of fibro-
blasts during ECM synthesis and their roles in controlling cell
migration or settlement along the specific 3D structure of organs
make them popular in tissue-engineering regenerative medicine
applications. Incorporation of fibroblast cells with endothelial cells
is a strategy for skin tissue regeneration, and autologous and allo-
geneic fibroblasts are frequently used for that purpose. However,
compared to allogeneic fibroblasts, autologous fibroblasts are asso-
ciated with better results, such as the low risk of rejection or cross
infection and improved skin regeneration.[168] A hierarchical
mechanismmediated by a transcription factor converts fibroblasts
into induced neural cells.[171] Fibroblasts in cardiac tissue
engineering maintain the ECM and provide a scaffold for cardiac
cell proliferation and homeostasis.[168] Originally derived from
liver tissue through the stem cell procedure, hepatocytes can
potentially be used in liver regeneration therapy.[172] A 3D hepa-
tocyte culture was able to maintain the liver’s metabolic system as
in an in vivo environment.[173] Human umbilical vein endothelial
cells (HUVECs), which originally come from endothelial veins in
the umbilical cord, are generally used for vasculature and angio-
genesis studies.[174] HUVECs are generally used for in vitro stud-
ies because they are relatively easy to isolate.[175] Moreover,
combining HUVECs with a suitable biomaterial is a promising
tissue-engineering strategy for regenerative medicine purposes.
5. Biophysical Cell Responses in Tissue
Engineering
The hierarchical scaffold in engineered tissue is important to
provide the cells’ microenvironment, including the ECM, bio-
chemical soluble factors, a biophysical field, and surrounding
cells, to give mechanical stimuli to the cells that elaborate many
aspects of cellular physiology, such as migration, growth, differ-
entiation, and survival.[11,13] The scaffold, regardless of whether it
is a synthetic or a natural scaffold, modulates cell behaviors for
functional tissue regeneration.[176] Mechanotransduction is a
sensing and responding process of cells to mechanical stimuli
that occur when cells attach to a biomaterial substrate’s surface.
The mechanical stimuli are converted into biochemical signals
from ECM to the nucleus. This process involves a combination
of receptor- and mechanical-mediated signals that will regulate
the cell’s phenotype and function.[14,15]
5.1. Mechanotransduction and Mechanosignaling
Mechanotransduction starts when integrin receptors in the cell
membrane attach to the ECM components in the scaffold.
Integrins, a superfamily of cell adhesion receptors, are hetero-
meric molecules assembled in α and β subunits that are nonco-
valently linked to various ECM components, and the
combination of those subunits defines the ECM component
and the cell type.[177,178] The extracellular domain of an integrin
receptor binds to an ECM molecule while the intracellular
domain interacts with cytoskeletal actin in the cytoplasm.
Cellular binding to the extracellular domain of an integrin recep-
tor is mediated by direct ligation to a specifically defined
sequence of ECM molecules.
Integrins that bind to appropriate protein sequences tend to
cluster on the cell membrane, which has a positive effect on link-
age formation with the ECM and leads to concentrated configu-
ration regions of integrins adjacent to the ECM. These links are
known as focal adhesions (FAs), and they allow communication
between the extracellular and the intracellular environments. The
FA complex has two classes of mechanotransduction proteins
that coincide as follows: proteins acting as mechanosensors by
converting the conformation in response to mechanical stimuli
and proteins acting as mechanoeffectors by recruiting down-
stream effectors in response to mechanical stimuli.[15,179]
After integrins bind to ECMmolecules, they bind to the cytoskel-
eton and promote intracellular reorganization, thus maintaining
the cell’s shape and internal architecture.[180] Integrin binding
with the contractile actomyosin machinery is crucial to the sub-
strate’s mechanics and mechanosensing.[181] On the basis of
molecular interactions, the tripeptide, arginine-glycine-aspartate
(RGD)-binding integrin clusters in which β3 integrin binds to a
number of components in the ECM and α2β1 integrin binds to
GFOGER, an amino sequence mostly containing collagen mol-
ecules, were very extensively studied, and in tissue engineering,
incorporating those integrin clusters into the scaffold was found
to be a strategy with potential for enhancing cell adhesion.[182–184]
In the cytoplasm, β-integrins bind to the globular head domain
of talin, a mechanosensor that activates talin’s mechanorespon-
sive properties by introducing cryptic vinculin binding sites and
mediating the formation of an F-actin and vinculin com-
plex.[185,186] This activation process stimulates the association
of cytoskeletal proteins, including vinculin, talin, alpha actinin,
the Src family of kinases, and FA kinase (FAK), to form a FA
complex.[187] Autophosphorylation activates FAK, which exerts
its signaling functions via phosphorylation of downstream tar-
gets, such as the Src family of kinases and paxillin, resulting
in the regulation of mechanotransduction and the dynamics
of FA turnover.[187,188] The dynamic turnover of talin and vincu-
lin is regulated by their activation states, thus activating down-
stream signaling to Rho-family GTPases. The activation of
Rho leads to higher contractility and FA growth whereas the
Rac activity increases the actin polymerization at the leading
edge.[181] Cell adhesion through vinculin activates nuclear locali-
zation of a YAP (yes-associated protein 1) and its coactivator
PDZ-binding motif (TAZ), which is regulated by the substrate’s
stiffness and the cell’s geometry. Once this complex is activated
and translocated to the nucleus, it modulates numerous gene
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transcriptions.[189] The YAP/TAZ complex has been extensively
studied as a critical regulator of stem-cell differentiation and cell
proliferation, as well as organ overgrowth and survival, by pairing
it with DNA-binding factors of the TEA domain (TEAD) fam-
ily.[190–192] In tissue engineering, the effect of the scaffold on cel-
lular behavior is mostly concerned with YAP/TAZ complex
regulation in the cells.
Even though integrin is responsible for the adhesion of cells to
the surrounding ECM, growth factors have been found to be
involved in these integrin-dependent processes.[192] The sum
of cell responses arising from growth factors depends not only
on the type of growth receptor but also on the cell, the receptor
type, and the intracellular receptor signaling pathway. The same
growth factor molecule binding to the same receptor may induce
different cellular responses in different cell types.[191] Cellular
responses triggered by growth factor signaling include cell sur-
vival, migration, proliferation, and differentiation into a specific
cell lineage.[191,192] A certain type of growth factor molecule rep-
resents a heparin-binding domain, which exhibits ECM binding
through integrin to elicit a specific cellular response.
Interestingly, the optimal stimulation of a growth factor mostly
depends on integrin-mediated cell adhesion to the appropriate
ECM. Many studies have revealed how to modulate the integrins
and growth factor receptors in a bidirectional way, for instance,
β1 integrin and epithelial growth factor receptor interactions in
epithelial cells.[193] Cross talk between integrins and growth fac-
tor receptors (Figure 6) is crucial for sustaining and determining
normal development and pathological processes in vascular biol-
ogy. Growth factors, such as epidermal growth factor, fibroblast
growth factor, platelet-derived growth factor, insulin-like growth
factor, fibroblast bone morphogenetic protein-2, and VEGF, have
been extensively developed by incorporating them with biomate-
rials for tissue engineering.[13,190]
5.2. Chemical Compositions and Manipulating Cell Responses
The chemical properties of the scaffold affect the behavior of
stem cells to determine the cell’s fate.[194–196] A collagen-I scaf-
fold was found to induce mouse embryonic stem cells to differ-
entiate into cardiomyocytes with or without a RGD peptide and
in combination with laminin.[194,197] In contrast, when that scaf-
fold was combined with fibronectin or laminin, embryonic stem
cells were strongly driven to endothelial cell differentiation and
vascularization.[194] On a synthetic polymer scaffold, such as a 3-
butyrate-cohydroxyhexanoate (PHBHHx) or an alginate scaffold,
the RGD peptide is conjugated to enhance cell attachment and to
nurture chondrogenic differentiation of bone marrow-derived
MSCs.[198,199] The combination of a natural ECM and a synthetic
scaffold, such as a collagen nanofibrous and PLGA scaffold with
recombinant fibronectin and cadherin 11 incorporated, was
found to enhance the proliferation of MSCs, induce osteogenic
gene expression (alkaline phosphatase, RUNX2, and osteocalcin)
and hold potential for bone tissue engineering.[37] If desirable cell
behaviors are to be achieved, control of the chemical composition
of the scaffold is a crucial factor for providing biophysical cues to
cells during functional hierarchical tissue assembly.
Every tissue has its own stiffness as defined by Young’s mod-
ulus or its own elasticity; thus, in tissue engineering, matrix
Figure 6. Schematic representation of the mechanotransduction signaling pathway involved in cell–scaffold interactions. This process starts at the FA site
when integrin engages the scaffold with varying stiffness and chemical compositions (e.g., collagen, laminin, fibronectin, and growth factor) to assemble
other proteins, such as talin, vinculin, FAK, and paxillin. This complex directly regulates F-actin assembly and dynamics and further activates YAP/TAZ
complexes. These complexes then translocate into the nucleus to stimulate downstream gene transcription with TEAD coactivator transcription. This
signaling propagates when the growth factor receptor directly links to integrin.
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stiffness is important for determining cell responses to mimic
the real conditions of tissue. The effects of substrate stiffness
on cell migration and FAs were extensively studied to reveal
the mechanical properties of the cell’s response.[13,200–203]
Cells can migrate easier on a soft or less-stiff substrate than
on a stiff substrate.[203] Cell–scaffold binding generates a huge
force from the cytoskeleton via an actin–myosin complex and
guides mature FA and the high organization of the cytoskeleton
on a stiff substrate (Figure 6). In contrast, on a soft substrate,
cells cannot generate enough counterbalance to develop stress
fibers.[204] Matrix stiffness influences cell morphology due to
cytoskeleton organization: on a soft scaffold, cells are round
while on a stiffer scaffold, cells tend to spread. The cellular
responses to stiffness are clearly observed through nuclear trans-
location of the YAP/TAZ complex. The higher the ECM stiffness
is, the larger the YAP/TAZ translocation to the nucleus via active
transcription is.[189] In a stiff 2D hydrogel, the YAP/TAZ nuclear/
cytoplasmic ratio is larger whereas it is smaller for a stiff 3D
gel.[205]
Geometry and ligand spacing control play essential roles in
orchestrating mechanotransduction, mimicking the tissue’s
length scale and directing stem cell differentiation.[41] Cell geom-
etry controls the nuclear translocation of the YAP/TAZ complex
to activate the transcription of some genes, and in the interme-
diate adhesion area, it can also direct the differentiation of
MSCs.[189] Decreasing the size of MSCs by modulating the sur-
face topography via nanopatterning was found to induce differ-
entiation into an adipogenic lineage by increasing the FA and the
YAP/TAZ nuclear translocation.[2] Cells with rectangle and star
shapes preferred cell osteogenesis. In contrast, cells with square
and flower shapes favored adipogenesis.[206] If the tissue’s phys-
iological length scale is to be mimicked, the spacing between
adhesive molecules in the ECM micropattern needs to be pre-
cisely controlled.[41] A larger micropatterning space (>73 nm)
reduces cell spreading and attachment, significantly limiting
the configuration of FAs and actin stress fibers.[207] Moreover,
another study showed that the local order of ligand arrangement
influenced the integrin clustering and the cell adhesion induced
by RGD ligands. When the substrate spacing arrangement is
wider than 70 nm, cell adhesion is inactivated by the RGD nano-
pattern order while it is activated by the RGD nanopattern
disorder.[208]
Taken all together, the cellular response to the microenviron-
ment via mechanosignaling has been found to induce integrin
binding to the scaffold. In tissue engineering, this biophysical
response is increased by selecting a biomaterial with an appro-
priate chemical composition for scaffold fabrication, by modify-
ing incorporated biological constituents, and/or by using the
mechanical properties of the scaffold, such as its geometry,
stiffness, and topography. Cutting-edge work on scaffold
development addresses the fabrication of a controllable multi-
component structure that mimics a biological cell-derived
scaffold[209] to support cell growth and control differentiation.
Therefore, controlling all those factors to achieve the desired goal
is crucial in tissue engineering.
5.3. Micro and Macroenvironments for Cellular Responses
Since the beginning of the tissue-engineering era, researchers
have tried to develop materials with uniform microscale or nano-
scale structures. Although these can induce the cell migration
and proliferation required for tissue repair, their efficiencies
were quite inferior compared to those of scaffolds with hierarchi-
cal structures that consist of both microsize and nanosize struc-
tures, as shown in Figure 7A.[210] In fact, overall cellular
activities, including cell migration, orientation, proliferation,
and differentiation, have been shown to be dramatically
enhanced when scaffolds fabricated with a hierarchical structure
are used. One reason for that better performance is the effective
distribution of the stress over a large area, thus increasing the
scaffold’s toughness in general.[211] Moreover, the hierarchical
organization has been adopted in nature by many species to
Figure 7. A) Schematic illustration of the effect of surface topography (flat, micro, nano, and hierarchical) on cellular responses. Reproduced with per-
mission.[210] Copyright 2014, Wiley-VCH. B) Increased immune responses of cells in a hierarchical microchannel scaffold in vivo: i) SEM images of cells
(yellow) attached to scaffolds at 24 h, ii) fluorescence images of extracellular DNA stained with SYTOX (green) and nuclei stained with DAPI (blue), and iii)
ratio of blue/green fluorescence intensities from image (ii). Reproduced with permission.[215] Copyright 2020, Elsevier.
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prevent the accumulation of somatic mutations.[212] This empha-
sizes the influence of hierarchical-based scaffolds on cell prolif-
eration and differentiation during tissue healing.
Despite all the benefits of hierarchical structures, their manu-
facture is still a challenge to tissue engineers.[213] One must have
a fair amount of knowledge about the structure of the target tis-
sue to be able to mimic its hierarchical design from the molecu-
lar to the macroscopic level. A common example is the structure
of bone in which nanoscale attributes affect cell binding, micro-
scale components affect cell migration, and macroscale struc-
tures affect the mechanical anisotropy of the bone.[214] One
method to enhance the hierarchical structure to mimic the
Haversian canals in bone is to use electrophoretic deposition
of a positive replica of chitosan/bioactive-glass scaffolds to create
similar micropores, thus augmenting osteoconduction.[213]
Taking a further step based on recent technical advancements,
researchers have successfully manufactured hierarchically struc-
tured 3D-printed scaffolds called “μCh.”[215] The interconnected
3D hierarchical structure in the microchannels can provide more
space for efficient nutrient transport and metabolic waste dis-
posal, thus enhancing osteogenesis.[216] Moreover, hierarchical
structures with appropriate micropatterns can efficiently manip-
ulate macrophage response by either increasing or reducing the
macrophage polarization, thus altering the osteogenic differenti-
ation of human bone marrow stromal cells.[217] These special
scaffolds were also reported to enhance bone regeneration signif-
icantly in an early stage by reducing the formation of neutrophils
(Figure 7Bi) while increasing cell survival as well as proliferation
within the wounded tissue in an early stage (Figure 7Bii–iii).[215]
This is a step closer to reproducing the natural bone–tissue struc-
ture and even further enhancing its functional activities.
Other targets of scaffolds based on hierarchical structures
have also been extensively researched in recent years.
Previous studies showed that hierarchical micro/nanofibrous
structures can weaken the differentiation of fibroblasts into myo-
fibroblasts, decreasing the excessive formation of the ECM and
promoting the production of a continuous neodura tissue with
characteristics similar to those of native skin tissue.[218] Tissue
engineering of skeletal muscles has also achieved good results
by incorporating micro/nanofibers into the hierarchical scaf-
folds. Such a structure was shown to encourage fiber alignment
by affecting the expression of various myogenic genes, such as
MyoD, myogenin, and troponin T, leading to increased myoblast
proliferation and myotube formation.[219] Stem-cell engineering
has also had noticeable success in creating microporous chitin
microspheres (PCMSs) that contain interconnected nanopores,
micropores, and macropores in a hierarchical porous structure,
thereby creating interconnected nanofibril networks to retain the
integrity of the PCMS. This leads to a remarkably improved pro-
liferation and adhesion of human embryonic stem cells.[217]
6. Implementation of Hierarchical Tissue
Constructs
Tissue engineering has been continuously developing over the
past decades. Technical advances, as well as knowledge from
related fields, such as materials science and engineering,[220]
3D printing technology,[18] nanotechnology, and cellular and
developmental biology,[221,222] have been assimilated and have
led to the promising implementation of both artificial tissue
for drug development and disease modeling and personalized
tissue engineering therapies in regenerative medicine.
However, one of the common obstacles in developing and using
artificial tissue is the current lack of ability to mimic the complex-
ity of the tissue’s structure and its natural microenviron-
ment.[223–225] Therefore, in this article, we discussed recent
developments and applications of fabricated artificial tissues with
a hierarchical concept for regenerative medicine, including its
utilization in pharmaceutical and pathophysiological research.
The inability of a 2D monolayer cell culture to resemble accu-
rately and reliably a disease model has led to the emergence of
microfluidic cell culture systems. The incorporation of a 2D cell
culture into a microfluidic device has led to 3D approaches with
sophisticated designs that mimic the mechanical and dynamic
environments of native tissue.[226] Fabrication of complex, aniso-
tropic, hierarchical macrostructures has been achieved by com-
bining and integrating different technologies and materials.
Bahmaee et al. used a fabrication method based on a polymerized
high-internal-phase emulsion (polyHIPE) to advance an
osteogenesis-on-a-chip device that incorporated a 3D environ-
ment and fluid shear stresses.[227] The channels inside the
polyHIPE introduce a multiscale porosity in the device, which
due to the hierarchical and interconnected porosity of
polyHIPE, can support proliferation, differentiation, and ECM
production.
As an implant, artificial tissue is continuously or sporadically
in contact with body tissue or fluids to replace and restore the
function of the native tissue that has been damaged. An implant-
able, multilayered (epidermis to dermis), and vascularized bioen-
gineered skin graft for use with nonhealing cutaneous ulcers was
fabricated using 3D bioprinting[228] and showed a vascular bed
self-assembled from human endothelial cells with or without
human placental pericytes in the dermal layer. Vascularization
in a perfused implant is a sign of an artificial tissue that can adapt
to its surrounding environment because the impregnated cells
are supplied with nutrients until full in-growth of functional
blood vessels from the surrounding host tissue is achieved.[229]
Comparably, Kim et al. printed a vascularized skin patch from
porcine-skin-derived dECM on immunodeficient mice by using
both the extrusion and the inkjet printing methods.[230]
Moreover, Cui et al. developed a cardiac patch with a 4D physi-
ologically adaptable design, which included hierarchical macro
and microstructural transformations tuned to the dynamic,
mechanical process of a beating heart.[231] Recently, the first
in-human cardiac bioimplant, named PeriCord, was implanted
as an advanced-therapy medicinal product in injured myocar-
dium clinical trials.[232] The bioimplant incorporates
Wharton’s jelly-MSCs from the umbilical cord as the active ingre-
dient and human decellularized, lyophilized, and sterilized peri-
cardium as the supporting cell material (vehicle) for surgical
implantation. Decellularized tissues or organs contain natural
hierarchical nano, micro, and macrostructures of endogenous
tissues that do not require further biofunctionalization.[233]
Differently from the implant constructed using a bioprinting pro-
cess, decellularized matrices represent the closest constructs to
natural ones.
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7. Present Challenges and Perspectives
Ideally, the 3D microarchitecture and the mechanical and bio-
chemical cues of tissue of interest have to be emulated in the
fabrication of tissue-engineered constructs if the implant is to
be integrated structurally and functionally in the body.[234]
Among the preparation methods to set up a biomaterial-based
scaffold, microfluidics and 3D bioprinting technology excel
due to their precision, controllability, and versatility in preparing
personalized biomaterials and complex tissues/organs. Advances
in 3D printing have increased the feasibility of fabricating hier-
archical tissues. For that reason, optimizing the microarchitec-
tures of biopolymers and improving the efficacy of bioprinting
are areas of active research. Furthermore, hydrogels and biopol-
ymers that are biocompatible may not always be suitable for use
with conventional bioprinting methods,[235] and the delivery of a
particular number of cells may not be consistent for many tissue
types.[236] One possible approach to addressing these issues
involves combining substances to maximize the utility of each
and to yield mechanical properties that can maintain the cell’s
functions under the mechanical and physical forces imposed
by the printing and the postprinting processes.
Similarly, the identification of alternative materials for OOC
devices is emerging as an important area of research, and
PDMS is becoming the most commonly used material in micro-
fluidic systems; however, it has drawbacks as the resultant film
is thicker than the in vivo morphology, the absorbance changes
of small hydrophobic molecules influence the efficacy of the sol-
vent, and the material is toxic.[58] Hierarchical construct
approaches in microfluidic technologies can provide the minimal
function of a native tissue or organ to transform pharmaceutical
preclinical examination by increasing throughput whileminimiz-
ing the ethical and the financial concerns associated with in vivo
assessment. The 3D bioprinting fabrication process for creating
the complex structure of a natural organ and/or tissue and the
microfluidic system to provide a microenvironment for the cell
are the critical points in successfulhierarchical tissueengineering.
Accordingly, an adaptable microenvironment through the
selection and the modification of suitable biomaterials is needed
to modulate the behaviors of cells during tissue regeneration.[11]
For the purpose of constructing a hierarchical tissue in regen-
erative medicine, a comprehensive understanding of the materials,
the fabrication method, the microenvironment, and the interac-
tions between cells and scaffolds is fundamental. Moreover, the
scaffold’s mechanical properties, such as stiffness, geometry,
and topography, which can induce biophysical responses, need
to be considered. In addition, the material’s degradation time
and the controlled release of biochemical signaling molecules
can affect the artificial tissue’s cellular response. Thus, efforts to
optimize the biomaterial’s utilization, the microarchitecture of
the artificial tissue, and the efficacy of the fabrication method
are crucial for achieving more practical, hierarchical, adaptable,
integrated scaffold–cell constructs for medical applications.
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